Literature DB >> 23519289

Costs and health outcomes associated with primary vs secondary care after an asthma-related hospitalization: a population-based study.

Mohsen Sadatsafavi1, Mark FitzGerald2, Carlo Marra3, Larry Lynd3.   

Abstract

BACKGROUND: Patients with a history of asthma-related hospitalizations are at high risk of readmission and generally consume a large amount of health-care resources. It is not clear if the secondary care provided by specialists after an episode of asthma-related hospitalization is associated with better outcomes compared with the primary care provided by general practitioners.
METHODS: Using population-based administrative health data from the province of British Columbia, Canada, we created a propensity-score-matched cohort of individuals who received primary vs secondary care in the 60 days after discharge from asthma-related hospitalization. Total direct asthma-related medical costs (primary outcome) and health service use and measures of medication adherence (secondary outcomes) were compared for the next 12 months.
RESULTS: Two thousand eighty-eight individuals were equally matched between the primary and secondary care groups. There was no difference in the direct asthma-related costs (difference $567; 95% CI, -$276 to $1,410) and rate of readmission (rate ratio [RR] = 1.06; 95% CI, 0.85-1.32) between the secondary and the primary care groups. Patients under secondary care had a higher rate of asthma-related outpatient service use (RR = 1.22; 95% CI, 1.11-1.35) but a lower rate of short-acting β-agonist dispensation (RR = 0.91; 95% CI, 0.85-0.98). The proportion of days covered with a controller medication was higher among the secondary care group (difference of 3.2%; 95% CI, 0.4%-6.0%).
CONCLUSIONS: Compared with those who received only primary care, patients who received secondary care showed evidence of more appropriate treatment. Nevertheless, there were no differences in the costs or the risk of readmission. Adherence to asthma medication in both groups was poor, indicating the need for raising the quality of care provided by generalists and specialists alike.

Entities:  

Mesh:

Year:  2013        PMID: 23519289     DOI: 10.1378/chest.12-2773

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  5 in total

1.  Family-initiated dialogue about medications during family-centered rounds.

Authors:  Jessica M Benjamin; Elizabeth D Cox; Philip J Trapskin; Victoria P Rajamanickam; Roderick C Jorgenson; Holly L Weber; Rachel E Pearson; Pascale Carayon; Nikki L Lubcke
Journal:  Pediatrics       Date:  2014-12-15       Impact factor: 7.124

2.  The Impact of Care Specialty on Survival-Adjusted Medical Costs of COPD Patients After a Hospitalization: a longitudinal analysis.

Authors:  Wenjia Chen; Don D Sin; J Mark FitzGerald; Mohsen Sadatsafavi
Journal:  J Gen Intern Med       Date:  2018-04-02       Impact factor: 5.128

3.  Asthma-Related Outcomes in Patients Initiating Extrafine Ciclesonide or Fine-Particle Inhaled Corticosteroids.

Authors:  Dirkje S Postma; Richard Dekhuijzen; Thys van der Molen; Richard J Martin; Wim van Aalderen; Nicolas Roche; Theresa W Guilbert; Elliot Israel; Daniela van Eickels; Javaria Mona Khalid; Ron M C Herings; Jetty A Overbeek; Cristiana Miglio; Victoria Thomas; Catherine Hutton; Elizabeth V Hillyer; David B Price
Journal:  Allergy Asthma Immunol Res       Date:  2017-03       Impact factor: 5.764

Review 4.  The role of hospitals in bridging the care continuum: a systematic review of coordination of care and follow-up for adults with chronic conditions.

Authors:  Melissa De Regge; Kaat De Pourcq; Bert Meijboom; Jeroen Trybou; Eric Mortier; Kristof Eeckloo
Journal:  BMC Health Serv Res       Date:  2017-08-09       Impact factor: 2.655

5.  Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy.

Authors:  David M G Halpin; Marjan Kerkhof; Joan B Soriano; Helga Mikkelsen; David B Price
Journal:  Respir Res       Date:  2016-09-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.